These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

697 related articles for article (PubMed ID: 30719715)

  • 1. Anlotinib, a novel small molecular tyrosine kinase inhibitor, suppresses growth and metastasis via dual blockade of VEGFR2 and MET in osteosarcoma.
    Wang G; Sun M; Jiang Y; Zhang T; Sun W; Wang H; Yin F; Wang Z; Sang W; Xu J; Mao M; Zuo D; Zhou Z; Wang C; Fu Z; Wang Z; Duan Z; Hua Y; Cai Z
    Int J Cancer; 2019 Aug; 145(4):979-993. PubMed ID: 30719715
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preclinical characterization of anlotinib, a highly potent and selective vascular endothelial growth factor receptor-2 inhibitor.
    Xie C; Wan X; Quan H; Zheng M; Fu L; Li Y; Lou L
    Cancer Sci; 2018 Apr; 109(4):1207-1219. PubMed ID: 29446853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anlotinib suppresses tumor progression via blocking the VEGFR2/PI3K/AKT cascade in intrahepatic cholangiocarcinoma.
    Song F; Hu B; Cheng JW; Sun YF; Zhou KQ; Wang PX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Cell Death Dis; 2020 Jul; 11(7):573. PubMed ID: 32709873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib inhibits angiogenesis via suppressing the activation of VEGFR2, PDGFRβ and FGFR1.
    Lin B; Song X; Yang D; Bai D; Yao Y; Lu N
    Gene; 2018 May; 654():77-86. PubMed ID: 29454091
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Met tyrosine kinase inhibitor, PF-2341066, suppresses growth and invasion of nasopharyngeal carcinoma.
    Zhao Y; Zhang J; Tian Y; Xue C; Hu Z; Zhang L
    Drug Des Devel Ther; 2015; 9():4897-907. PubMed ID: 26345996
    [TBL] [Abstract][Full Text] [Related]  

  • 7. HGF/NK4, a four-kringle antagonist of hepatocyte growth factor, is an angiogenesis inhibitor that suppresses tumor growth and metastasis in mice.
    Kuba K; Matsumoto K; Date K; Shimura H; Tanaka M; Nakamura T
    Cancer Res; 2000 Dec; 60(23):6737-43. PubMed ID: 11118060
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
    Zheng B; Ren T; Huang Y; Guo W
    Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
    Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
    PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor activity of anlotinib in malignant melanoma: modulation of angiogenesis and vasculogenic mimicry.
    Yang Q; Li Q; Fan H
    Arch Dermatol Res; 2024 Jul; 316(7):447. PubMed ID: 38958761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Formononetin, a novel FGFR2 inhibitor, potently inhibits angiogenesis and tumor growth in preclinical models.
    Wu XY; Xu H; Wu ZF; Chen C; Liu JY; Wu GN; Yao XQ; Liu FK; Li G; Shen L
    Oncotarget; 2015 Dec; 6(42):44563-78. PubMed ID: 26575424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bevacizumab promotes active biological behaviors of human umbilical vein endothelial cells by activating TGFβ1 pathways
    Zhang X; Zhang Y; Jia Y; Qin T; Zhang C; Li Y; Huang C; Liu Z; Wang J; Li K
    Cancer Biol Med; 2020 May; 17(2):418-432. PubMed ID: 32587778
    [No Abstract]   [Full Text] [Related]  

  • 13. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth.
    Yakes FM; Chen J; Tan J; Yamaguchi K; Shi Y; Yu P; Qian F; Chu F; Bentzien F; Cancilla B; Orf J; You A; Laird AD; Engst S; Lee L; Lesch J; Chou YC; Joly AH
    Mol Cancer Ther; 2011 Dec; 10(12):2298-308. PubMed ID: 21926191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective treatment of anlotinib in giant delayed pulmonary metastasis of osteosarcoma: a case report and literature review.
    Long ZY; Lu Y; Li M; Chen G; Shi L; Xiao X; Bai Y; Zhang HM; Wang Z
    Ann Palliat Med; 2021 Jun; 10(6):7073-7082. PubMed ID: 33548989
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
    Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
    Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
    [TBL] [Abstract][Full Text] [Related]  

  • 16. KRC-408, a novel c-Met inhibitor, suppresses cell proliferation and angiogenesis of gastric cancer.
    Hong SW; Jung KH; Park BH; Zheng HM; Lee HS; Choi MJ; Yun JI; Kang NS; Lee J; Hong SS
    Cancer Lett; 2013 May; 332(1):74-82. PubMed ID: 23348694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anlotinib Inhibits Cell Proliferation, Migration and Invasion via Suppression of c-Met Pathway and Activation of ERK1/2 Pathway in H446 Cells.
    Tang X; Zheng Y; Jiao D; Chen J; Liu X; Xiong S; Chen Q
    Anticancer Agents Med Chem; 2021; 21(6):747-755. PubMed ID: 32682383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PI3K inhibitor impairs tumor progression and enhances sensitivity to anlotinib in anlotinib-resistant osteosarcoma.
    Chen C; Guo Y; Huang Q; Wang B; Wang W; Niu J; Lou J; Xu J; Ren T; Huang Y; Guo W
    Cancer Lett; 2022 Jun; 536():215660. PubMed ID: 35318116
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel inhibitor of c-Met and VEGF receptor tyrosine kinases with a broad spectrum of in vivo antitumor activities.
    Awazu Y; Nakamura K; Mizutani A; Kakoi Y; Iwata H; Yamasaki S; Miyamoto N; Imamura S; Miki H; Hori A
    Mol Cancer Ther; 2013 Jun; 12(6):913-24. PubMed ID: 23548264
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sinomenine prevents metastasis of human osteosarcoma cells via S phase arrest and suppression of tumor-related neovascularization and osteolysis through the CXCR4-STAT3 pathway.
    Xie T; Ren HY; Lin HQ; Mao JP; Zhu T; Wang SD; Ye ZM
    Int J Oncol; 2016 May; 48(5):2098-112. PubMed ID: 26983669
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.